Company or ticker...

Intellia Therapeutics

Intellia develops CRISPR gene-editing therapies for genetic diseases.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

NTLA

1.7B

29.8

n/a

27.84%

Key Facts

M. Cap

PS

PE

YTD

1.7B

29.8

n/a

27.84%

10MA

20MA

50MA

200MA

$NTLA